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The bactericidal action of two therapeutic regimens on Mycobacterium tuberculosis wa  assessed by
viable counts in serial sputum samples in 49 pulmonary tuberculosis patients being treated with
rifampicin (R), etbambutol (Emb), isoniazid (I) and pyrazinamide (Z) together in a single dose thrice
weekly (REmbIZ3) or with REmb and IZ on alternate days (REmb3IZ3alt). In both groups of patients,
there was a significant reduction (P < 0.02) in the colony forming units (cfu) of M. tuberculosis per
ml of sputum during the first two days of treatment itself. This early bactericidal action (EBA) as well
as the reduction in counts during the subsequent days of treatment were similar (P > 0.2) for both
REmbIZ3 and REmb3IZ3alt regimens indicating that splitting up REmbIZ into REmb on one day and
IZ on the next day in short course chemotherapy (SCC) regimens may not affect the bactericidal action
of the regimens.
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In most of the short course chemotherapy (SCC)
regimens of 6-8 months’ duration, four drugs, viz.,
rifampicin (R), isoniazid (I), pyrazinamide (Z) and
streptomycin (S) or ethambutol (Emb) are given to-
gether, usually for two months initially, in a single
dose either daily or intermittently1. Since the amount
of the drugs to be consumed by the patients in a
single dose is large in such regimens, patient compli-
ance may be adversely affected. Further, murine stud-
ies have suggested that there could be antagonism
between I and R when these two drugs are given
together most probably due to pharmacological inter-
action2,3. These interactions could be overcome by
splitting the 4 drugs into: two, 2-drug combinations
(REmb & IZ), giving each combination on alternate
days, thus making each 2-drug combination intermit-
tent. A controlled clinical trial is in progress at the
Tuberculosis Research Centre, Madras to study
whether administration of the two 2-drug combina-
tions on alternate days would be as effective as all 4
drugs given together.
In an earlier study, using an in vitro system, we
found that R, Emb, I and Z together thrice weekly
had as good early bactericidal action (EBA) on
Mycobacterium tuberculosis strains as REmb and IZ
on alternate days4. Although in vitro models5,6, mac-
rophage systems7-9 and murine tuberculosis models10
can be used to study the bactericidal action of such
regimens on M. tuberculosis, it would be more ap-
propriate to study this in patients with pulmonary
tuberculosis1l.
The present study was undertaken in patients being
treated for pulmonary tuberculosis to determine the
bactericidal action on M. tuberculosis when REmb
and IZ are given on alternate days, in comparison with
REmbIZ given together thrice weekly, by carrying out
viable counts in serial sputum samples.
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Material & Methods
Study subjects : Adult, sputum culture positive, pul-
monary tuberculosis patients with no history of pre-
vious treatment were included in the study. Patients
with drug-resistant organisms initially were excluded.
Regimens : The patients were randomly allocated to
receive R, Emb, I and Z together in a single dose
thrice weekly (REmbIZ3), or REmb and IZ on alter-
nate days (REmb3IZ3alt). From the total number of
patients randomly allocated to the two regimens,
those with negative cultures on day 0 (before start of
treatment), and those who failed to attend or whose
cultures were contaminated at any of the subsequent
time points (days 2, 4, 9 and 16 after starting treat-
ment) were excluded from the analysis leaving 21
patients in the REmbIZ3 group and 28 in the
REmb3IZ3alt group.
The dosages were the same for both the regimens,
namely, rifampicin 450 mg, ethambutol 1000 mg and
pyrazinamide 1.5g for patients weighing 40.0 kg or
less, and 600 mg,1200 mg and 2.0 g, respectively,
for patients weighing 40.1 kg or more. The dosage of
isoniazid was 600 mg, irrespective of body weight.
Sputum collection :Sputum was collected overnight
in sterile wide mouth containers by the patients and
brought to the Centre on day 0 (before start of treat-
ment) and on days 2, 4, 9 and 16 after starting
treatment. The samples were given code numbers to
conceal their identity before they were processed in
the laboratory.
Sputum viable count : The number of colony forming
units (cfu) of M. tuberculosis per ml of sputum
sample was determined following the method of
Jindani et al11. Briefly, within 1 h of receiving a
coded sample in the laboratory, it was homogenized
by shaking first with large glass beads and then with
10 per cent dithiothreitol (Sputolysin). The mixture
was centrifuged at 3000 rpm for 1.5 min, and the
deposit resuspended in sterile distilled water. From
this, viable counts were set up on 7H11 medium
plates made select ive with polymyxin B,
carbenicillin, trimethoprim and amphotericin B12. At
the end of 4 wk of incubation, the number of colonies
in the plates was counted using a colony counter and
the cfu per ml of neat sputum was obtained.
Table I. Mean log10 cfu/ml of M. tuberculosis in serial sputum samples of
patients treated with REmbIZ3 and REmb3IZ3alt
Treatment Mean log10 cfu/ml ± SD on (day)
0 2 4 9 16
REmbIZ3 6.99±1.64 5.58±1.65 4.59±2.13 3.17±1.91 2.79±1.77
(n=21)
REmb3IZ3alt 6.29±2.08 5.39±2.05 4.89±1.83 3.581±1.98 2.76±1.60
(n=28)
Using the methods described above, in another
experiment, cfu/ml was determined in sputum
samples collected from 19 untreated pulmonary tu-
berculosis patients on two consecutive days to find
out the intrapatient variation.
Analysis of data : The mean log10 cfu/ml of M. tuber-
culosis in the sputum samples in the two groups of
patients before start of treatment (day 0) and on days
2, 4, 9 and 16 during treatment were calculated. In
less than 10 per cent of the occasions there were no
detectable colonies in the viable count. To facilitate
handling of data, a count of 1 was uniformly added
resulting in a log value of 0 for a negative culture.
The change per day in 0-2 days and 2-16 days were
computed for each patient and an RBD analysis
undertaken in patients on each of the two regimens.
The difference between the two regimens in the dif-
ferences was also tested using a t-test for indepen-
dent observations.
Results
The mean log10 cfu/ml of M. tuberculosis n the
sputum samples of the two groups of patients
(REmbIZ3 and REmb3IZ3alt) before start of treatment
(day 0) and on days 2, 4, 9 and 16 during treatment
are presented in Table I. In the two groups of pa-
tients, the log,, cfu/ml in sputum on day 0 were fairly
similar, viz.. 6.99 and 6.29, respectively (P > 0.2).
In the REmbIZ3 group, on day 2, after one dose of
REmbIZ3 the mean count became 5.58. This reduc-
tion was significant (P < 0.01). By day 16 the count
reached 2.79. Similarly, in the REmb3IZ3alt group,
by day 2, after the patients had received one dose of
REmb and one dose of IZ, the mean count became
5.39, and this reduction was also significant (P=0.02).
By day 16, the count was reduced to 2.76.
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In the REmbIZ3 regimen, the early bactericidal
action (EBA), estimated as the change in log10 cfu/
ml/day during the first two days (0-2 days) of treat-
ment was 0.71 (Table II), and the rate of reduction
in counts during the subsequent days (2-16 days) was
0.20; the former was significantly higher than the
latter (P < 0.05). The corresponding values in the
REmbIZ3alt regimen were 0.45 and 0.19, and were
not significantly different (P > 0.1). The EBA of
REmb3IZ3alt regimen (0.45) was not significantly
different from that of REmbIZ3 regimen (0.71)
(P=0.36), and the reduction in counts during the
subsequent days (0.19 and 0.20, respectively) was
very similar. These results indicated that the bacte-
ricidal action on M. tuberculosis in pulmonary tuber-
culosis patients for REmbIZ3 and REmb3IZ3alt regi-
mens may not be different.
In the experiment carried out to determine
intrapatient variation, the log10 cfu/ml of M. tubercu-
losis in two consecutive sputum samples from 19
untreated pulmonary tuberculosis patients were 7.21
(SD 1.49, range 4.08 - 8.74) and 7.38 (SD 1.57,
range 3.28 - 9.04), respectively. By using ANOVA
it was seen that the variation between patients was
substantially greater (SD 2.12) than the variation
between duplicate samples from the same patients
(SD 0.44) providing evidence of consistent differ-
ences between patients.
Discussion
The results of this study in tuberculosis patients
support the preliminary evidence obtained by us from
an earlier in vitro study4. In the in vitro experiment,
the bactericidal action of pulsed exposure to R,
Emb, I and Z together thrice weekly and split up into
REmb and IZ on alternate days was studied using
cultures of M. tuberculosis H37Rv, 2 isolates of M.
tuberculosis ensitive to these drugs as well as 4
isolates resistant to one or more drugs. Both the
treatment procedures had equally good bactericidal
action on M. tuberculosis strains in the in vitro sys-
tem and the differences were not statistically signifi-
cant (P > 0.1). In the present in vivo study also
REmbIZ3 and REmb3IZ3alt had similar (P > 0.3)
early bactericidal action. The EBA of the REmb3IZ3alt
regimen was not smaller than that of the REmbIZ3
regimen.
Table II. Mean change in log10 cfu/ml/day of M. tuberculosis in
sputum of patients treated with REmbIZ3 and REmb3IZ3
Treatment
REmbIZ3
(n=21)
Mean change in log10 cfu/ml/day±SD between days
0-2 2-16 0-16
0.71±0.95 0.20±0.17 0.26±0.11
REmb3IZ3alt
(n=28)
0.45±0.93 0.19±0.15 0.22±0.15
P= 0.36 0.83 0.29
There was also no evidence of increased EBA of
REmb3IZ3alt regimen compared to the REmbIZ3 regi-
men, excluding any antagonism between I and R in
EBA in the present study. In the murine model ex-
periments carried out by Grosset and associates,2,3
the bactericidal activities of IRZ and IR were similar
whereas that of RZ was significantly greater. The
relapse rate was significantly smaller in the group of
mice treated with RZ in the continuation phase than
in the groups treated with IRZ (or IR). These results
in the murine model had suggested that antagonism
occurred between I and the combination RZ. In the
present study, no antagonism could be seen in the
EBA; whether it would be reflected in the sterilizing
effect and relapse rates of the regimens remains to be
seen.
The reduction in the rate of elimination of viable
bacilli after the first week of treatment seen in the
study by Jindani et al11 was observed in the present
investigation also. As observed by them, the early
faster rate of elimination is probably determined by
the inherent bactericidal activity of the drug regi-
mens against the large number of actively growing
M. tuberculosis in the cavitary walls which are com-
parable to logarithmic phase cultures in vitro, whereas
the later slower rate is determined by the almost
dormant physiologic state of the surviving organisms
independent of the drug regimens employed.
The standard deviation for EBA (change in log,,
cfu/ml/day between days 0 and 2) in the present
study was 0.95 with the REmbIZ3 regimen and 0.93
with the REmb3IZ3alt regimen (coefficient of varia-
tions being 134 and 207%, respectively) which were
much larger than those observed in similar studies
and the Clinic and Nursing Staff of Tuberculosis Research Centre.
Madras, for organising the sputum collection and drug administration.
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with other antituberculosis drugs and combin tions
carried out by others in Nairobi11 and in Hong Kong13.
This variation was 0.19 (60 d.f.) in the Nairobi study
and 0.38 (84 d.f.) in the Hong Kong study. It was
considered by the latter group of workers13 that the 1.
larger variation between Hong Kong patients than
between the Nairobi patients could be due to charac-2.
teristics of the pulmonary lesions in these patients.
The much larger variation seen in the present study
is due to the gross heterogeneity in the response to
3.
treatment in the patients in our study. Because of the
large standard deviations observed in the present
study, even a decreased activity of 36 per cent with4.
the REmbI3IZ3alt regimen in the first 2 days was not
found to be statistically significant. A computation
of ‘post-facto power’ calculation revealed that the
power of the test with the present sample size was5.
less than 50 per cent. A similar finding was noticed
also between the two regimens in the reduction be-
tween 2-4 days, again due to the large standard de-6.
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To summarise, the results of the present study
suggest that splitting up REmbIZ into REmb on one
day and IZ on the next day in SCC regimens may not
affect the EBA of the regimens. On the other hand,
this will help in reducing the bulk of the drugs to be
consumed and may help in compliance. Treatment of
patients with these two regimens is in progress at this
Centre and the results of this study will reveal whether
splitting up REmbIZ into REmb and IZ will help in
reducing adverse reactions. Further, EBA is not an
indicator of the sterilising ability of regimens. The
sterilising ability and effectiveness of a regimen in
chemotherapy can be estimated only based on spu-
tum conversion rates and relapse rates11 which will
soon be available from the on-going clinical trial at
the Centre.
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